Literature DB >> 9513763

Elimination of drugs by the new polyamide hemofilter FH77H during various in vitro conditions.

U F Kroh1, G K Dinges, P Lukasewitz, W U Steinhäusser, T J Holl, H Lennartz.   

Abstract

BACKGROUND/AIMS: Multiple organ failure alters the dosage of drugs during hemofiltration. To separate factors, we utilized in vitro hemofiltration to investigate different blood flows, protein concentrations and intracellular drug partition with the FH77H polyamide membrane.
METHODS: One liter of warm heparinized fresh human blood was hemofiltrated in two series: (1) with digoxin, netilmycin, phenobarbital, ceftriaxone and teicoplanin, and (2) with amikacin, theophylline, ceftazidim, phenytoin and vancomycin and, in addition, with cell-free fresh frozen plasma.
RESULTS: The increased volumes of distribution of aminoglycosides and theophylline were a combined result of partition into cells and adsorption into the filter membrane. The deviations of drug sieving from predicted values were due to different affinities of the drugs on whole blood binding sites.
CONCLUSION: The in vitro composition of drugs and blood improved the detection of factors that influence drug elimination during hemofiltration. The FH77H polyamide hemofilter facilitates more precise predictions of drug dosages by low adsorption rates to the membrane.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513763     DOI: 10.1159/000014313

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  2 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.